Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 7

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
 by accounting principles generally accepted in the
United States of America. The accompanying unaudited condensed consolidated financial statements should therefore be read in conjunction
with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2024 included in the Company’s
Annual Report on Form 10-K. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly
owned subsidiaries. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will
continue as a going concern. In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments
of a normal recurring nature necessary for a fair presentation of the results for the interim period presented.

     8 

Significant Accounting Policies 

There have been no material changes to the Company’s
significant accounting policies during the three and six months ended June 30, 2025, as compared to the significant accounting policies
disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2024.

Recently Adopted Accounting Standards 

There have been no additional accounting pronouncements
adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) during
the three and six months ended June 30, 2025, as compared to the recent accounting pronouncements described in Note 2 of the Company’s
Annual Report on Form 10-K for the year ended December 31, 2024, that the Company believes are of significance or potential significance
to the Company.

    3.
    Fair Value of Financial Instruments

Under this authoritative guidance, we are required
to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We determine fair value
based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using
market interest rates commensurate with the credit quality and duration of the investment or valuations by third-party professionals.
The three levels of inputs that we may use to measure fair value are:

    ·
    Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

    ·
    Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

    ·